Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study (Lancet Oncology, 2013)

(untitled) - Robert, C; Dummer, R; Gutzmer, R; Lorigan, P; Kim, K; Nyakas, M; Arance, A; Liszkay, G; Schadendorf, D; Cantarini, M; Spencer, S; Middleton, MR